Skip to main content

Table 3 COX univariate and multivariate analyses in patients with EGFR-mutant stage IV NSCLC

From: Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs

Variables

Univariate analysis

Multivariate analysis

 

HR(95%CI)

P

HR(95%CI)

P

Sex

    

Female

Reference

   

Male

1.11(0.86—1.44)

0.416

  

Age (years)

    

< 60

Reference

 

Reference

 

≥ 60

1.34(1.03—1.73)

0.029

1.20(0.91—1.58)

0.191

Stage

    

IVA

Reference

 

Reference

 

IVB or IVC

1.55(1.20—2.01)

<0.001

0.94(0.69—1.29)

0.698

Smoking status

    

No

Reference

   

Yes

1.24(0.94—1.62)

0.124

  

Hypertension

    

No

Reference

   

Yes

1.10(0.81—1.51)

0.540

  

Diabetes

    

No

Reference

   

Yes

1.40(0.78—2.50)

0.262

  

Coronary disease

    

No

Reference

   

Yes

0.80(0.41—1.57)

0.521

  

Pathology type

    

Adenocarcinoma

Reference

 

Reference

 

Non-adenocarcinoma

2.11(1.18—3.77)

0.012

3.57(1.95—6.54)

<0.001

EGFR mutation

 

0.304

  

19del

Reference

   

L858R

1.24(0.94—1.62)

0.126

  

Other mutations

1.04(0.62—1.75)

0.882

  

Pleural metastasis

    

No

Reference

   

Yes

0.87(0.66—1.14)

0.311

  

Liver metastasis

    

No

Reference

 

Reference

 

Yes

1.87(1.12—3.12)

0.016

2.15(1.23—3.77)

0.007

Brain metastasis

    

No

Reference

 

Reference

 

Yes

1.94(1.40—2.70)

<0.001

1.94(1.30—2.88)

0.001

Bone metastasis

    

No

Reference

   

Yes

1.16(0.89—1.51)

0.270

  

Adrenal gland metastasis

    

No

Reference

   

Yes

1.61(0.99—2.60)

0.055

  

Intrapulmonary metastasis

    

No

Reference

   

Yes

0.89(0.67—1.18)

0.430

  

Malignant pleural effusion

    

No

Reference

   

Yes

1.29(0.89—1.88)

0.178

  

Other metastasis

    

No

Reference

   

Yes

1.17(0.78—1.74)

0.455

  

CEA

    

Negative

Reference

 

Reference

 

Positive

1.55(1.16—2.07)

0.003

1.24(0.91—1.70)

0.180

SCC

    

Negative

Reference

   

Positive

1.19(0.82—1.72)

0.352

  

NSE

    

Negative

Reference

 

Reference

 

Positive

1.82(1.40—2.38)

<0.001

1.43(1.06—1.92)

0.019

ProGRP

    

Negative

Reference

 

Reference

 

Positive

1.37(1.04—1.79)

0.024

1.21(0.89—1.65)

0.227

CYFRA 21 − 1

    

Negative

Reference

 

Reference

 

Positive

2.35(1.80—3.06)

<0.001

1.77(1.31—2.41)

<0.001

EGFR-TKIs

 

0.022

 

<0.001

Osimertinib

Reference

 

Reference

 

Icotinib

1.54(1.10—2.16)

0.012

2.49(1.71—3.60)

<0.001

Gefitinib

1.14(0.72—1.79)

0.581

1.89(1.13—3.16)

0.015

Immunotherapy

    

No

Reference

   

Yes

0.69(0.42—1.12)

0.133

  

Lung surgery

    

No

Reference

   

Yes

0.34(0.11—1.06)

0.064

  

Metastasis surgery

    

No

Reference

   

Yes

0.81(0.30—2.19)

0.682

  

Radiotherapy

    

No

Reference

 

Reference

 

Yes

0.58(0.44—0.76)

<0.001

0.62(0.47—0.83)

<0.001

Chemotherapy

    

No

Reference

 

Reference

 

Yes

0.52(0.40—0.68)

<0.001

0.51(0.38—0.67)

<0.001

  1. P-values were calculated using the Wald test in the Cox regression analysis. CEA, carcinoembryonic antigen; CI, confidence interval; CYFRA 21 − 1, cytokeratin-19 fragments; EGFR, epidermal growth factor receptor; EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors; HR, hazard ratio; mOS, median overall survival; NSE, neuron-specific enolase; ProGRP, progastrin-releasing peptide; SCC, squamous cell carcinoma antigen
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us